Page 56 - Read Online

Kalloo et al. Metab Target Organ Damage 2023;3:7 https://dx.doi.org/10.20517/mtod.2022.26 Page 17 of 19

combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes
(VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519-29. DOI PubMed
18. Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older
adults with type 2 diabetes. Diabetes Ther 2021;12:1227-47. DOI PubMed PMC
19. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-announced-safety-review-has-found-type-2-diabetes-
m e d i c i n e s - c o n t a i n i n g - s a x a g l i p t i n -
and#:~:text=On%20April%205%2C%202016%2C%20FDA,have%20heart%20or%20kidney%20disease [Last accessed on 23 May
2023].
20. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and
mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. DOI
21. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events
in type 2 diabetes. N Engl J Med 2017;377:644-57. DOI PubMed
22. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2
diabetes. N Engl J Med 2019;380:347-57. DOI PubMed
23. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart
failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. DOI PubMed
24. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin
in heart failure. N Engl J Med 2020;383:1413-24. DOI PubMed
25. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and
nephropathy. N Engl J Med 2019;380:2295-306. DOI PubMed
26. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with
chronic kidney disease. N Engl J Med 2020;383:1436-46. DOI PubMed
27. Bauersachs J. SCORED and SOLOIST: the next scores for SGLT2 inhibitors. Cardiovasc Res 2021;117:e49-51. DOI PubMed
28. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved
ejection fraction. N Engl J Med 2021;385:1451-61. DOI PubMed
29. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and
preserved ejection fraction: the EMPEROR-preserved trial. Circulation 2022;145:184-93. DOI PubMed PMC
30. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure
[Last accessed on 24 May 2023].
31. Available from: https://www.medicines.org.uk/emc/product/5441/smpc#gref [Last accessed on 24 May 2023].
32. Hasegawa K, Lewis BS. Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction? Eur Heart J
Cardiovasc Pharmacother 2022;8:E10. DOI PubMed
33. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with
mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-98. DOI PubMed
34. Verma S, Leiter LA, Zinman B, et al. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG
OUTCOME trial. ESC Heart Fail 2021;8:2603-7. DOI PubMed PMC
35. Berg DD, Jhund PS, Docherty KF, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization
in patients with heart failure with reduced ejection fraction. JAMA Cardiol 2021;6:499-507. DOI PubMed PMC
36. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced
ejection fraction: the EMPEROR-reduced trial. Circulation 2021;143:326-36. DOI PubMed PMC
37. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a
multinational randomized trial. Nat Med 2022;28:568-74. DOI PubMed PMC
38. Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in
patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 2022;146:279-88. DOI PubMed PMC
39. Koufakis T, Mustafa OG, Ajjan RA, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk
worth taking? J Clin Pharm Ther 2020;45:883-91. DOI PubMed
40. Khunti K, Aroda VR, Bhatt DL, et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors
during acute illness: a perspective based on the updated evidence. Diabetes Obes Metab 2022;24:2071-80. DOI PubMed
41. Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-
19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021;9:586-94. DOI
PubMed PMC
42. Fralick M, Colacci M, Thiruchelvam D, Gomes T, Redelmeier DA. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl
peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus. Diabetes Obes
Metab 2021;23:950-60. DOI PubMed
43. Available from: https://www.easd.org/media-centre/home.html%20#!resources/b-safety-and-efficacy-of-sglt2-inhibitors-in-over-70-
years-old-type-2-diabetic-patients-1-year-of-follow-up-b-bac06cfd-6ee4-4476-a43d-096cb7d74cd4 [Last accessed on 24 May 2023].
44. Yabe D, Shiki K, Suzaki K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled,
52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese
patients with type 2 diabetes. BMJ Open 2021;11:e045844. DOI PubMed PMC